ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2116

No Adverse Effects of Veverimer on Volume Status or Blood Pressure in Patients with CKD and Metabolic Acidosis

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials


  • Wesson, Donald E., Baylor Scott & White Health and Wellness Center, Dallas, Texas, United States
  • Mathur, Vandana S., MathurConsulting, Woodside, California, United States
  • Tangri, Navdeep, University of Manitoba, Winnipeg, Manitoba, Canada
  • Stasiv, Yuri, Tricida, Inc., South San Francisco, California, United States
  • Parsell, Dawn, Tricida, Inc., South San Francisco, California, United States
  • Li, Elizabeth, PharmaStat LLC, Fremont, California, United States
  • Klaerner, Gerrit, Tricida, Inc., South San Francisco, California, United States
  • Bushinsky, David A., University of Rochester Medical Center, Rochester, New York, United States

Current American Heart Association guidelines recommend sodium (Na) restriction of <1.5 g/day. Drugs can be a source of Na, potentially contributing to inadequate control of blood pressure (BP) and volume. For example, each NaHCO3 tablet (650 mg) contains 170 mg of Na and multiple tablets per day are required to effectively treat metabolic acidosis.

Veverimer is a non-absorbed polymer that treats metabolic acidosis by binding and removing HCl from the GI tract. It is not an exchange resin and does not introduce unwanted cations such as Na or K. We hypothesized that veverimer would not increase BP, weight or induce volume overload. In Phase 3 randomized, blinded placebo-controlled trials in acidotic patients (pts) with CKD (baseline mean eGFR 29 mL/min/1.73 m2), veverimer significantly increased serum bicarbonate (LS mean +4.7 mEq/L at Week 52) with safety profile similar to placebo (Wesson et al. Lancet, 2019).


We analyzed parameters related to volume status in these Phase 3 trials.


In these studies, 97% and 31% of pts, had HTN and CHF, respectively and 193 pts were treated with veverimer or placebo for up to 52 weeks. Treatment with veverimer (v placebo) had no effect on weight, BP, urine Na/creatinine ratio, volume-related adverse events, or increased use of diuretics or antihypertensives (Table).


Veverimer, a novel non-absorbed HCl binder, effectively treats metabolic acidosis in CKD without adversely affecting BP or volume status.

 Placebo (N = 81)Veverimer (N = 112)
Mean (SD) Change from Baseline to Week 52
BP (systolic/diastolic, mmHg)-2.0 (7.1)/-2.9 (5.8)-2.0 (7.6)/-2.6 (8.0)
Body Weight (kg)0.5 (2.2)-0.3 (2.7)
Urine Na/Creatinine (mol/mol)1.10 (10.35)-0.08 (13.32)
Patients with Selected Adverse Events during 52-Week Study
Congestive Heart Failure4 (4%)3 (2%)
Hypertension4 (4%)7 (6%)
Peripheral Edema3 (3%)0
Patients Starting Selected Medications during 52-Week Study
Diuretics8 (9%)8 (6%)
Antihypertensives5 (5%)9 (7%)

Data presented are mean (SD) or n (%)


  • Commercial Support